Recent editions
- April 2012
Kathy Pritchard on key breast cancer research presented at EBCC-8 in Vienna. - March 2012
EORTC Director General Françoise Meunier discusses the challenges faced today by clinical researchers in cancer. - February 2012
Mary O'Brien discusses an impressive trial of lung cancer screening using low-dose CT. - January 2012
Rob Coleman discusses combinations of targeted agents in hormone-sensitive breast cancer. - December 2011
Manuela Schmidinger on new agents for the treatment of renal cell cancer. - November 2011
Gordon Mills assesses the challenges we face in developing personalised medicine. - October 2011
Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable. - September 2011
Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
EJC News Focus – February 2012
The largest ever screening trial in lung cancer reported last year that screening with low-dose CT reduces mortality from the disease. This impressive trial, from the US’ National Lung Screening Trial Research Team, demonstrated that CT scans could detect both early stage and advanced disease. So – does that mean that lung screening is set to become a reality in many countries? Not in the short term, says EJC’s Lung Cancer Editor, Mary O’Brien (Royal Marsden Hospital, Sutton, Surrey, UK). She told Helen Saul that other ongoing trials will take between 5 and 10 years to report, and that these results will be needed to answer outstanding questions before expensive screening programmes can be considered. But in the meantime, she applauds the trial and says it holds important messages for both clinicians and patients.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening (N Engl J Med 2011; 365:395-409)